Condition
Pandemic Influenza Prevention
Total Trials
2
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Blb750 Vaccine Qinghai Rg Strain
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 4 (1)
Trial Status
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07111078Phase 1Recruiting
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
NCT03370289Phase 4CompletedPrimary
A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
Showing all 2 trials
Research Network
Common Treatments
- Blb750 Vaccine Qinghai Rg Strain1
- Vrcflumos012200vp1
- Alfq1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)1
- Takeda1
Top Investigators
National Institute of Allergy and Infectious Diseases (NIAID)
Related Conditions
- Influenza Prevention1